ALSIUS (ALUS) Misses Q3 EPS by 2c
More News related to ALUS
- ALSIUS (ALUS) Misses Q3 EPS by 2c
- Alsius (ALUS) Announces FDA Clearance to Market Solex(TM) Heat Exchange Catheter
- Ramius Capital Discloses 5.2% Stake in Alsius (ALUS)
More News related to Earnings
- RW Baird Makes Positive Comments on Incyte (INCY) Following Novartis Deal
- Incyte (INCY) Strikes Major Drug Development Deal with Noavartis
- Human Genome Sciences (HGSI) Submits BLA to U.S. FDA for Hep C Treatment ZALBIN
- Incyte (INCY) In License Agreement With Novartis, Worth Up to $1 Billion
- Gen-Probe (GPRO) Gets U.S. FDA Clearance for Marketing Prodesse's ProParaflu+ Assay
ALSIUS CORPORATION (Nasdaq: ALUS) reports a Q3 loss of $0.23, 2 cents worse than the analyst estimate of ($0.21). Revenue for the quarter was $3.1 million, versus the consensus of $3.66 million.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
